logo.png
Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024
January 31, 2024 08:45 ET | Autonomix Medical, Inc.
THE WOODLANDS, TX., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...
Emergen logo.png
Vascular access device Market Size Worth USD 10.90 Billion in 2032 | Emergen Research
January 29, 2024 11:00 ET | Emergen Research
Vancouver, Jan. 29, 2024 (GLOBE NEWSWIRE) -- The global vascular access device market size was USD 5.45 Billion in 2022 and is expected to register a rapid revenue CAGR of 7.1% during the forecast...
Logo.png
GRI Bio Announces Reverse Stock Split
January 26, 2024 08:05 ET | GRI Bio, Inc.
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...
Emergen logo.png
Osteoporosis Drugs Market Size Worth USD 20.53 Billion in 2032 | Emergen Research
January 18, 2024 10:15 ET | Emergen Research
Vancouver, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The global osteoporosis drugs market size was USD 13.06 billion in 2022 and is expected to register a revenue CAGR of 4.7% during the forecast period....
Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
January 09, 2024 08:00 ET | Palisade Bio, Inc.
Carlsbad, CA, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious...
US Neurologists Opti
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
January 03, 2024 09:46 ET | Spherix Global Insights
EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not...
BMS Attributes Sotyk
BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake
December 07, 2023 12:01 ET | Spherix Global Insights
Exton, PA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call,...
Logo.png
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
December 07, 2023 08:00 ET | Hepion Pharmaceuticals, Inc.
Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account...
Logo.png
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
December 05, 2023 09:05 ET | GRI Bio, Inc.
Clinical development plan potentially leveraging 505(b)(2) regulatory pathway Currently available treatments for IPF are limited to only two approved drugs that come with significant...
Dyadic Logo Current.jpg
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
November 29, 2023 08:30 ET | Dyadic International, Inc.
Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate